Drug Patents owned by Gilead Sciences
1. Drug name - ATRIPLA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8716264 | GILEAD SCIENCES | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 3 months from now) | |
| US9744181 | GILEAD SCIENCES | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 3 months from now) | |
| US8592397 | GILEAD SCIENCES | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 3 months from now) | |
| US9457036 | GILEAD SCIENCES | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 3 months from now) | |
| US9545414 | GILEAD SCIENCES | Unitary pharmaceutical dosage form |
Jun, 2026
(3 years from now) | |
| US9018192 | GILEAD SCIENCES | Unitary pharmaceutical dosage form |
Jun, 2026
(3 years from now) | |
| US8598185 | GILEAD SCIENCES | Unitary pharmaceutical dosage form |
Apr, 2029
(6 years from now) | |
Drugs and Companies using EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient
Treatment: Treatment of hiv infection; Treatment of hiv-1 infection in pediatric patients 12 years of age and older; treatment of hiv-1 infection in adults; Treatment of hiv-1 infection in adults; treatment of hiv-1 infection in pediatric patients 12 years of age and older
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 600MG;200MG;300MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.